Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPE NASDAQ:HSTO NASDAQ:PXMD NASDAQ:ZSAN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00$0.00$0.00▼$0.13$3K5.09692 shs355 shsHSTOHistogen$0.00$0.00$0.05▼$0.55$1K1.1910,369 shs83 shsPXMDPaxMedica$0.00$0.00$0.00▼$0.00$2K-0.9911,821 shsN/AZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%-6.90%-97.93%+22.73%HSTOHistogen0.00%-60.00%-33.33%-83.33%-99.91%PXMDPaxMedica0.00%0.00%0.00%+100.00%-99.80%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.00$0.00$0.00▼$0.13$3K5.09692 shs355 shsHSTOHistogen$0.00$0.00$0.05▼$0.55$1K1.1910,369 shs83 shsPXMDPaxMedica$0.00$0.00$0.00▼$0.00$2K-0.9911,821 shsN/AZSANZosano Pharma$0.00$3.90$0.46▼$37.45$1K3.3425,375 shs5,685 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%-6.90%-97.93%+22.73%HSTOHistogen0.00%-60.00%-33.33%-83.33%-99.91%PXMDPaxMedica0.00%0.00%0.00%+100.00%-99.80%ZSANZosano Pharma0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/AHSTOHistogen 0.00N/AN/AN/APXMDPaxMedica 0.00N/AN/AN/AZSANZosano Pharma 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/AHSTOHistogen$19K0.04N/AN/A$3.13 per share0.00PXMDPaxMedicaN/AN/AN/AN/A$0.46 per shareN/AZSANZosano Pharma$790K0.00N/AN/A$9.74 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/AHSTOHistogen-$10.62M-$2.81N/A∞N/AN/AN/AN/AN/APXMDPaxMedica-$18.29MN/A0.00∞N/AN/A-3,167.89%-560.35%N/AZSANZosano Pharma-$29.92M-$14.50N/A∞N/A-8,375.11%-177.06%-119.14%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AHSTOHistogenN/AN/AN/AN/AN/APXMDPaxMedicaN/AN/AN/AN/AN/AZSANZosano PharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPEAmpio PharmaceuticalsN/AN/AN/AHSTOHistogenN/AN/AN/APXMDPaxMedicaN/A0.380.38ZSANZosano PharmaN/A1.611.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%HSTOHistogenN/APXMDPaxMedica4.90%ZSANZosano PharmaN/AInsider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%HSTOHistogen3.30%PXMDPaxMedica1.00%ZSANZosano Pharma2.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataHSTOHistogen204.27 millionN/ANot OptionablePXMDPaxMedica211.31 million11.20 millionNot OptionableZSANZosano Pharma404.90 million4.78 millionNot OptionableZSAN, AMPE, HSTO, and PXMD HeadlinesRecent News About These CompaniesMicroneedles for Drug Delivery Patent Landscape Report and Forecast 2024-2032, Featuring Minnesota Mining and Manufacturing, BD and Co, Zosano Pharma, Raphas, Nano, and Pass TechnologiesMarch 7, 2025 | globenewswire.comNifty PharmaAugust 2, 2024 | economictimes.indiatimes.comThe seven steps to selling in pharmaJuly 31, 2024 | pharmaphorum.comPAktuelle Empfehlungen zur ZOSANOJuly 28, 2024 | finanznachrichten.deHOOK HOOKIPA Pharma Inc.April 12, 2024 | seekingalpha.comNachrichten - Weitere NachrichtenJanuary 9, 2024 | wallstreet-online.deWLISTEN: Supreme Court hears arguments on legality of Purdue Pharma bankruptcy planDecember 6, 2023 | pbs.orgPDer Börsen-Tag: Diese US-Aktie stürzte nachbörslich abAugust 22, 2023 | n-tv.deNEast Bay Business NewsMay 18, 2023 | bizjournals.comMankind Pharma IPO opens on April 25, listing scheduled for May 9April 27, 2023 | moneycontrol.comAstellas PharmaApril 6, 2023 | forbes.comGiiant Pharma Receives Financial Support From the US Crohn’s and Colitis FoundationFebruary 5, 2023 | finance.yahoo.comFTC asks court to hold 'pharma bro' Martin Shkreli in contempt for failing to abide by ordersJanuary 23, 2023 | washingtonexaminer.comWZosano Pharma Corporation (ZSANQ)November 5, 2022 | ca.finance.yahoo.comNow bankrupt, Zosano sells off its drug delivery tech that once enticed Novo Nordisk, Eli LillyOctober 13, 2022 | endpts.comEBankrupt Zosano Sells Its Drug Delivery Tech That Once Partnered With Pharma GiantsOctober 12, 2022 | msn.comBankrupt Zosano Pharma Says Unsecured Creditors Will Recoup 28% of ClaimsAugust 28, 2022 | marketwatch.comEast Bay migraine patch developer Zosano closes sale in bankruptcy court for $1 millionAugust 27, 2022 | bizjournals.comZosano Pharma Corp (ZSANQ)August 24, 2022 | investing.comEast Bay company promised drug-coated microneedle patches. Now it could be sold in bankruptcy court for just $1MJuly 26, 2022 | bizjournals.comZSAN, AMPE, HSTO, and PXMD Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.0027 0.00 (0.00%) As of 09:41 AM EasternAmpio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Histogen NASDAQ:HSTO$0.0002 0.00 (0.00%) As of 09/8/2025Histogen Inc., a clinical-stage therapeutics company, focuses on developing clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function. The company's product candidates include emricasan for the treatment of acute bacterial skin and skin structure infections, as well as other infectious diseases. Its preclinical product candidates include CTS-2090 and CTS-2096, which are selective small molecule inhibitors of caspase-1 designed for the treatment of various inflammatory diseases. Histogen Inc. was founded in 2007 and is based in San Diego, California. On April 18, 2024, Histogen Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of California.PaxMedica NASDAQ:PXMD$0.0002 0.00 (0.00%) As of 09/8/2025PaxMedica, Inc., a clinical stage biopharmaceutical company, focuses on the development of anti-purinergic drug therapies for the treatment of disorders with intractable neurologic symptoms. Its lead product candidate is PAX-101 that is in Phase 3 clinical trials, an intravenous formulation of suramin for the treatment of autism spectrum disorder, myalgic encephalomyelitis/chronic fatigue syndrome, long COVID-19 syndrome, fragile X syndrome, human African trypanosomiasis (HAT), and fragile X-associated tremor/ataxia syndrome. The company is developing PAX-102, an intranasal formulation of suramin for neurologic indications, as well as other new chemical entities that are targeted and selective antagonists of purine receptor subtypes; and PAX-HAT-301 for the treatment of HAT. It has a research collaboration agreement with PolarMar Health for Phase II clinical trial in austism spectrum disorder for emodin, which retains the rights for PolarMar to develop and commercialize any non-prescription supplement form of the product, and for PaxMedica, Inc. to retain exclusive rights to develop and commercialize a highly purified form of emodin. The company was formerly known as Purinix Pharmaceuticals LLC and changed its name to PaxMedica, Inc. in April 2020. PaxMedica, Inc. was incorporated in 2018 and is based in Tarrytown, New York.Zosano Pharma NASDAQ:ZSANZosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation of zolmitriptan used for the acute treatment of migraine. The company was founded in 2006 and is headquartered in Fremont, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Casey’s General Stores: Investors Win With CASY at the Bat Should You Buy Figma Stock After Its 55% Post-IPO Drop? Ulta Beauty Stock: Strong Growth, Short-Term Volatility Ahead Joby's Stock Is Quiet, But a Storm of Catalysts Is Brewing The Quiet Before the Catalyst: Vertical Aerospace's Next Move Novartis' Moonshot Cancer Therapy Could Be Future Growth Driver Insiders Sell These High-Quality Stocks: Why Investors Shouldn’t 2 Small-Cap Dividend-Paying Retailers to Buy and Hold for 2026 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
